Let's discuss how I can help you achieve large exponential growth and secure large Pharma contracts. I am networking and interested in pursuing a North America Commercial role in sales and/or business development. Please let me know if you are aware of any opportunities that are a good fit or you can forward to the hiring managers.

1. Currently Seeking
Employment
Opportunities in Business
Development and Sales

3. Contact Rafael Casiano
at 813-330-7555
rafaelcasiano2@
gmail.com
 Top Commercial performer in 2016
 Built a very strong funnel and generated $8M in
contracts in Year 2018
 Increased the # of customers from 15 in 2015 to 40 in
2016
 Exceeded 2016 plan by $3M
 Finished 2016, 3x higher revenue than 2015
 Increased the # of customers from 3 in 2014 to 15 in
2015
 Double sales in 2015 vs. 2014

4. Accelerate Discovery and Development from a Single Slide

5. Challenges in Diagnostics Discovery and Development
Limited patient
tissue for
comprehensive
analysis
Implications
• Rapid sample depletion
• Insufficient data for stratification research
• Therapeutic options limited for patients
Protein Biomarkers
• Protein expression
• Phosphorylation
• Ligands / Growth factors
• Cell types
Genomic Biomarkers
• DNA
• RNA
• miRNA
• Sequencing
Complex Disease Biology
• Interactions of multiple
pathways
• Tumor heterogeneity
• Adaptive resistance
MultiOmyx enables comprehensive profiling,
improved diagnosis, and therapeutic options.
5

6. Immunoprofiling-Hot Application for MultiOmyx
Immune classification color blends
CD4 CD8 CD68 PD-L1
pan-CK CD68|PD-L1
CD4 CD8 CD68 PD-L1 pan-CK
Immunofluorescence color blends
MultiOmyx enables profiling
the types of immune cells
present in the tumor
6

7. Serial Sections (5µm)
FFPE Block
(10-30 µm)
Single Ab staining
CD4
CD8
CD19
CD45RO
Ki67
Different sections of a tissue being analyzed for different biomarkers may
lead to different results!
Challenges with assessing immune markers co-
expression in singleplexed assay
Co-expression Analysis
MO Multiplexed assay enables analysis of multiple immune markers
co-expression from a single slide
7

8. Hyperplexed: stain, image, erase and repeat
Dye Inactivation
>60 Proteins
8
PD-L1 PanCK
PD-L1 PanCK

9. CD8+ Ki67+
CD4+ CD45RO+ CD8+ CD45RO+
CD8+ Granzyme B+
CD8+ PD1+
“Memory” T Helper “Memory” TC
“effector” TC“Proliferating” TC “Anergic” TC
Immune cell co-expression
CD4+FoxP3+ “Regulatory” T cell
9

10. Immune Cell Co-localization
PanCK CD3 CD4 CD8 FoxP3 PD-L1 CD68
Tumor/PanCK+
CD3+CD4+
T helper
CD3+CD4+FoxP3+
T regulatory
PD-L1+CD68+
CD3+CD8+
T cytotoxic
Tumor Margin

11. Innate (tumor cell intrinsic) resistance Adaptive resistance

12. Visualization
Biomarker overlays
Biomarker co-expression
• Visualize co-localization of
markers
• Generate .png images for
publications and presentations
• Evaluate biomarker co-
expression
Biomarker heat maps
• Visualize heat maps of multiple
biomarkers for assessment of
expression and co-localization
Biomarker clusters
• Visualize results of cluster analysis
and explore the biosignatures
Molecular H&E Molecular DAB
• Conversion of fluorescent image to a
H&E appearance. Allows
interpretation in context of tumor
• Conversion of fluorescent
image to DAB appearance.
Familiar format for
pathologist
12
Cluster ID

13. Low Immune
Biomarker Cell
Counts
Density
in
Tumor
(#/mm2
)
Density
in
Stroma
(#/mm2
)
Tumor Cells 1386 NA NA
CD4+ 64 23.3 177.4
CD8+ 47 11.7 134.6
CD20+ 13 7.8 33.6
FOXP3+ 53 7.8 156.0
PDL1+ 0 0 0
Biomarker
High Immune
Cell
Counts
Density
in Tumor
(#/mm2
)
Density
in Stroma
(#/mm2
)
Tumor Cells 1692 NA NA
CD4+ 231 238.1 675.4
CD8+ 299 492.3 547.0
CD20+ 14 2.7 61.8
FOXP3+ 177 160.5 556.5
PDL1+ 234 246.1 675.4
HighImmuneLowImmune
Multiplexed IF Analytics Output
CK CD4 CD8 CD20 FOXP3 PD-
L1
CK CD4 CD8 CD20 FOXP3 PD-L1
CK CD4 CD8 CD20 FOXP3 PD-
L1
CK CD4 CD8 CD20 FOXP3 PD-L1
1
3
Immune Infiltration

14. MultiOmyx Tumor Infiltrating Lymphocyte Panel
O Provides quantitative analytical results and spatial
information of 12 cancer immune markers from every cell on
a single FFPE
14

15. Dyes are cycled by a
proprietary chemical
inactivation method
Gerdes et al (2013)
PNAS
Multiplexed Proteins
Protein + DNA FISH
15
CD4 CD8 CD68 PD-L1 pan-CK
DNA Sequencing (ROI)
Immune Phenotyping
- Up to 60 protein biomarkers can
be fluorescently imaged in a single
FFPE tissue section
- Additional “omics” such as
RNAScope, DNA FISH, and NGS
can be performed from the same IF
processed slide and analyzed with
protein data
- Advanced visualization of immune
biomarker co-expression and co-
localization
- Sophisticated algorithms identify
individual cells and measure
quantitative per-cell biomarker
and morphology profiles
MultiOmyx Technology Summary…

17. 17